ORIGINAL RESEARCH article

Front. Oncol., 04 November 2026

Sec. Hematologic Malignancies

Volume 16 - 2026 | https://doi.org/10.3389/fonc.2026.2002517

Stem cell mobilization with G-CSF and on-demand plerixafor in newly diagnosed multiple myeloma patients treated with daratumumab: a single-center experience

  • 1. University Medical Center Ljubljana, Ljubljana, Slovenia

  • 2. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Abstract

Introduction:

Daratumumab-containing induction therapy improves treatment response in transplant-eligible patients with newly diagnosed multiple myeloma but may impair hematopoietic stem cell mobilization. We evaluated the effect of daratumumab exposure on stem cell mobilization and collection and assessed the effectiveness of on demand plerixafor in patients with inadequate mobilization.

Methods:

We retrospectively analyzed 215 transplant-eligible patients with newly diagnosed multiple myeloma treated at a single center between January 2022 and February 2025. Patients underwent granulocyte colony-stimulating factor–based mobilization, with plerixafor administered on demand on the fourth day of mobilization. The primary endpoint was peripheral blood CD34+ cell concentration on day 4 of mobilization. Secondary endpoints included plerixafor use, number of apheresis procedures, total CD34+ cells collected, and mobilization failure.

Results:

Eighty-two patients received daratumumab-containing induction and 133 did not. The median peripheral blood CD34+ cell concentration on day 4 of mobilization was significantly lower after daratumumab exposure than without (9.61 vs 20.0 × 106 cells/L; P < 0.001). Plerixafor was required in 74.4% versus 39.8% of patients, respectively (P < 0.001). Among patients who received plerixafor, the median peripheral blood CD34+ cell concentration increased from 9.46 to 42.8 × 106 cells/L, with a comparable increase regardless of prior daratumumab exposure. Total CD34+ cells collected were lower after daratumumab exposure (mean 5.96 vs 6.98 × 106 cells/kg; P = 0.005), whereas mobilization failure remained uncommon (6% vs 4%).

Conclusion:

Daratumumab-containing induction is associated with impaired stem cell mobilization and an increased need for plerixafor. On demand plerixafor effectively overcomes poor mobilization, enabling successful stem cell collection in the vast majority of patients.

1 Introduction

Daratumumab is increasingly used as a key component of induction therapy in patients with newly diagnosed multiple myeloma (NDMM) and is associated with deeper treatment responses. Autologous stem cell transplantation (ASCT) remains a standard frontline procedure for transplant-eligible patients (1). However, daratumumab, particularly in combination with lenalidomide, may negatively affect hematopoietic stem cell (HSC) mobilization (2). Pivotal trials evaluating daratumumab-based induction regimens in NDMM have reported lower HSC yields in the experimental arms, leading to increased use of plerixafor to achieve successful mobilization and collection (3–5). Plerixafor is a selective, reversible antagonist of the CXCR4 receptor that inhibits its interaction with the ligand SDF-1α, thereby promoting the release of HSCs into the peripheral blood and potentially overcoming the adverse effects of daratumumab on HSC mobilization (6–9).

Our study was designed to evaluate the impact of daratumumab containing induction regimens on mobilization and total HSC yields in transplant eligible NDMM patients in routine medical practice and to provide additional real-world evidence of the effect of adding plerixafor in case of poor mobilizers.

2 Methods

2.1 Patients and procedures

Patients included in this single center, non-interventional, retrospective analysis were all transplant eligible NDMM patients referred to the University Medical Center Ljubljana for stem cell mobilization and ASCT between January 2022 and February 2025.

At our center, the target HSC dose for single ASCT is ≥2.5 × 106 CD34+ cells/kg body weight (BW). According to our institutional protocol, daratumumab is withheld for at least 3 weeks and lenalidomide for 14 days before the initiation of stem cell mobilization. Standard mobilization consists of granulocyte-colony stimulating factor (G-CSF) alone, administered subcutaneously at a dose of 10 µg/kg BW daily on days 1–4. Peripheral blood CD34+ cell counts are assessed on day 4 after initiation of stimulation. A threshold of ≥20 × 106 CD34+ cells/L in peripheral blood is required to proceed to apheresis. Poor mobilizers are defined as those who fail to achieve the peripheral blood threshold of ≥ 20 × 106 CD34+ cells/L on day 4 of mobilization. They proceed to receive plerixafor at the dose of 0.24 mg/kg BW the night before apheresis. An additional dose of plerixafor was administered after the first day of HSC collection at the treating physician’s discretion if the CD34+ cell yield was below 2.5 × 106 cells/kg when one transplant was planned or below 5.0 × 106 cells/kg when cells were being collected for two transplant procedures. Maximum of 2 doses of plerixafor are used. Mobilization failure is defined as failure to collect at least 2.5 × 106 CD34+ cells/kg BW for single ASCT. The standard is to collect HSC for two procedures, even though salvage ASCT is rarely used in the era of novel T cell directed therapies. In case of planned tandem ASCT, cells are collected for 3 procedures. Peripheral blood CD34+ cells were collected by leukapheresis using either the Spectra Optia® Apheresis System (Terumo BCT, Inc., Lakewood, CO, USA) or the AMICUS™ Separator System (Fresenius Kabi AG, Bad Homburg.

The primary endpoint of the study was the number of peripheral CD34+ cells on day 4 of G-CSF mobilization or day 10 of chemotherapy and filgrastim mobilization.

Secondary endpoints included the use of plerixafor, number of apheresis procedures, total CD34+ cells yield and number of mobilization failures.

This study received approval from institutional Ethics Committee (reference number KSEV-4-091225).

2.2 Statistical analysis

Continuous variables were evaluated for normality using the Shapiro-Wilk test. Where normality assumptions were met, independent-group comparisons were performed using the Welch two-sample t-test to account for potential inequalities in variances and sample sizes. Where normality assumptions were violated, independent groups were compared using the Wilcoxon rank-sum test, with the Hodges–Lehmann estimator and its 95% confidence interval reported as the effect size. Paired continuous measurements were analyzed using the Wilcoxon signed-rank test. Relationships between continuous variables were evaluated using Spearman rank correlation. Categorical variables were summarized as frequencies and percentages and compared between groups using the chi-square test, or Fisher’s exact test when expected cell counts were small. Multivariable logistic regression was used to identify independent predictors of binary outcomes while adjusting for candidate covariates. Statistical analyses were performed using R (version 4.5.2; R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were two-sided, and a p-value < 0.05 was considered statistically significant.

3 Results

A total of 215 patients were included, with 82 (38%) receiving daratumumab-containing induction and 133 (62%) treated without daratumumab. The median number of induction cycles was four in both groups, and demographic characteristics were comparable. High-risk cytogenetics was more frequent in the daratumumab cohort (31.7% vs. 12%). Pre-mobilization response differed significantly; ≥VGPR was achieved in 72% of patients treated with daratumumab compared with 45.9% in the non-daratumumab group (p<0.001). Type of mobilization regimen and myeloma subtype distribution were similar across cohorts (Table 1).

Table 1

MetricsDaratumumabNo daratumumabp
n82133
Male N (%)49 (59.8)74 (55.6)0.637
Female N (%)33 (40.2)59 (44.4)
Mobilization procedure0.419
Cylophosphamide + GCSF4 (4.9)8 (6.0)
GCSF only77 (93.9)125 (94.0)
Other1 (1.2)0 (0.0)
Age Median (Q1–Q3)60 (54–64)61 (55–65)
Myeloma type N (%)
Asecretory1 (1.2)1 (0.8)
BJ kapa19 (23.2)12 (9.0)
BJ lambda9 (11.0)7 (5.3)
Extramedullary1 (1.2)0 (0.0)
IgA kapa6 (7.3)22 (16.5)
IgA lambda2 (2.4)7 (5.3)
IgD lambda1 (1.2)2 (1.5)
IgG kapa27 (32.9)55 (41.4)
IgG lambda12 (14.6)25 (18.8)
IgM lambda0 (0.0)2 (1.5)
Plasma cell leukemia4 (4.9)0 (0.0)
Bone marrow infiltration at diagnosis. Median (Q1–Q3)70% (42.5–80)52.5% (30–70)
Cytogenetic Risk N (%)
HR26 (31.7)16 (12.0)
SR41 (50.0)88 (66.2)
Unknown15 (18.3)29 (21.8)
Lenalidomide induction N (%)0.092
Yes65 (79.3)90 (67.7)
No17 (20.7)43 (32.3)
Median number of induction cycles44
Response N (%)p < 0.001
≥ VGPR59 (72.0)61 (45.9)
PR16 (19.5)66 (49.6)
SD4 (4.9)2 (1.5)
Unknown3 (3.6)4 (3)

Patients´demographics.

GCSF, granulocyte- colony stimulating factor; HR, high risk; SR, standard risk; VGPR, very good partial response; PR, partial response; SD, stable disease.

Most used daratumumab containing regimen was DVRD (daratumumab, bortezomib, lenalidomide, dexamethasone) (61/82), followed by triplets such as DVD (daratumumab, bortezomib, dexamethasone), DRD (daratumumab, lenalidomide, dexamethasone), DPD (daratumumab, pomalidomide, dexamethasone). Only a few patients received DVTD (daratumumab, bortezomib, thalidomide, dexamethasone), since thalidomide was replaced by lenalidomide due to unavailability on our market. Daratumumab exposure was associated with lower peripheral blood CD34+ cell concentration on day 4 of mobilization (median, 9.61 vs 20.0; Hodges-Lehmann location shift, 9.85; 95% CI, 6.6-13.8; Wilcoxon rank-sum test, P <.001) and with a higher rate of plerixafor use (74.4% vs 39.8%; odds ratio [OR], 4.35; 95% CI, 2.30-8.46; P <.001) (Figures 1A, B). Lenalidomide exposure was associated with lower peripheral blood CD34+ cell concentration on day 4 of mobilization (median, 14.0 vs 19.7; Wilcoxon rank-sum test, P = .021) and with a higher rate of plerixafor use (60.0% vs 35.0%; OR, 2.77; 95% CI, 1.44-5.47; P = .001). No significant associations with either outcome were observed for age, gender, or cytogenetic risk group. In logistic regression including daratumumab and lenalidomide exposure, daratumumab (adjusted OR, 4.16; 95% CI, 2.28–7.84; P <.001) and lenalidomide (adjusted OR, 2.55; 95% CI, 1.34–4.96; P = .005) were each associated with higher odds of plerixafor use.

Figure 1

Among the 114 patients who received plerixafor, CD34+ cell concentration in peripheral blood increased from a median of 9.46 × 106 CD34+ cells/L to 42.8 × 106 CD34+ cells/L after plerixafor use. Every patient in this subgroup showed an increase (Figure 1C). The Hodges-Lehmann pseudomedian increase was 33.9 (95% CI, 30.0-38.5; P <.001). The magnitude of this increase did not differ significantly between patients with and without daratumumab exposure (Figure 1D). The absolute increase in CD34+ cell concentration was numerically similar between daratumumab-exposed and non-exposed patients (median, 30.0 vs 35.7; Wilcoxon rank-sum test, P = .10), as was the relative (fold) increase (median, 5.4-fold vs 4.9-fold; P = .38). Among plerixafor-treated patients, daratumumab exposure was associated with an adjusted post-plerixafor CD34+ geometric mean ratio of 0.88 (95% CI 0.74–1.06; P = 0.169), after adjustment for pre-plerixafor CD34+ and lenalidomide exposure. The corresponding adjusted ratio for lenalidomide exposure was 1.12 (95% CI 0.89–1.41; P = 0.334). Neither exposure showed a statistically significant association with post-plerixafor CD34 +. These findings indicate that although daratumumab exposure was associated with lower baseline CD34+ cell mobilization it did not affect plerixafor rescue.

The median number of apheresis procedures was two in daratumumab exposed and non-exposed patients. Total collected CD34+ cells were significantly lower in the daratumumab-exposed group: mean 5.96 × 106 CD34+ cells/kg vs 6.98 × 106 CD34+ cells/kg (mean difference 1.02, 95% CI: 0.32–1.73), Welch’s t-test p = 0.005. Mobilization failure occurred in five patients (6%) in the daratumumab group and in five patients (4%) in the non-daratumumab group (Table 2).

Table 2

Metric/outcomeDaratumumabNo daratumumabStatistical test & significance
Peripheral blood CD34+ on day 4 of mobilization (median)9.6120.0Wilcoxon rank-sum test, P <.001
Plerixafor use (rate)74.4%39.8%OR 4.35, P <.001
Absolute increase in CD34+ post-plerixafor (median)30.035.7Wilcoxon rank-sum test, P = .10
Relative increase post-plerixafor (median fold)5.4-fold4.9-foldP = .38
Number of apheresis procedures (median)22
Total CD34+ collected (mean, x 106 cells/kg)5.966.98Welch’s t-test, P = 0.005
Mobilization failure (n, %)5 (6%)5 (4%)

Stem cell collection parameters and plerixafor use and efficacy.

4 Discussion

The results from our study demonstrated that daratumumab-containing induction therapy is associated with impaired stem cell mobilization, but a structured on-demand plerixafor use enables successful collection and ASCT in nearly all patients. Our findings are consistent with published data from randomized trials and real-world cohorts, which indicate that daratumumab reduces HSC yield and increases plerixafor dependency, yet does not preclude transplant feasibility when modern mobilization approaches are employed (2, 3, 6, 10, 11).

Our cohort comprised 82 patients who received daratumumab-containing induction and 133 who did not, with the mobilization regimen being predominantly G-CSF alone (94% in both groups). We observed a significantly lower peripheral blood CD34+ cell concentration on day 4 of mobilization in daratumumab-exposed patients (median 9.61 vs. 20.0 cells × 106 CD34+ cells/L; p<0.001), which mirrors the intrinsic mobilization impairment reported across the literature (2, 3, 6, 10). The magnitude of this impairment appears more pronounced than in studies using cyclophosphamide-based chemo mobilization, such as the Italian multicenter D-VTd study where the median yield was 7.6 × 106 CD34+ cells/kg (2), or the CASSIOPEIA trial where chemo mobilization with cyclophosphamide and G-CSF resulted in median yields of 6.3 × 106/kg in the D-VTd arm (3). This is consistent with the notion that steady-state (G-CSF-only) mobilization may be more susceptible to the negative effects of daratumumab on CD34+ cell egress than chemo-mobilization-based approaches (11).

Plerixafor use was substantially higher in the daratumumab group (74.4% vs. 39.8%; OR 4.35, p<0.001), consistent with the 30–64% plerixafor rates reported in other daratumumab-treated cohorts (2, 6, 11). The MASTER and GRIFFIN trial analysis found that plerixafor was used in 97% of D-KRd patients and 72% of D-VRd patients (10), while the VTd versus D-VTd comparison with G-CSF plus on-demand plerixafor reported plerixafor use in 53% of D-VTd patients versus 28% with VTd (7). Our rate of 74.4% falls within this range and reflects the real-world necessity of plerixafor rescue after steady-state mobilization in patients exposed to daratumumab. In the logistic regression model including daratumumab and lenalidomide exposure, both lenalidomide (adjusted OR 2.55, p=0.005) and daratumumab (adjusted OR 4.16, p<0.001) remained associated with plerixafor use after adjustment for the other exposure. This two-variable model does not establish an independent effect of daratumumab, because other differences between the cohorts were not accounted for. This is consistent with the known negative impact of IMiD exposure on stem cell mobilization and supports the observation from the MASTER/GRIFFIN analysis that longer lenalidomide duration (16 weeks in MASTER vs. 12 weeks in GRIFFIN) was associated with higher plerixafor use and lower yields (10, 12, 13).

A key observation was that plerixafor effectively rescued mobilization regardless of prior daratumumab exposure, with similar absolute and relative CD34+ cell increases (median fold-increase 5.4 vs. 4.9, p=0.38). This finding is concordant with the published evidence that on-demand plerixafor compensates for the lower baseline mobilization efficiency seen after daratumumab, reducing outright collection failures and allowing most patients to reach target yields (2, 3, 10, 11). The literature shows that plerixafor is the key intervention that preserves collection success in daratumumab-treated patients (9, 14, 15), and our data provide a quantitative confirmation of this effect using pre- and post-plerixafor CD34+ cell measurements. Despite the lower intrinsic mobilization capacity, cumulative CD34+ cell yields in our daratumumab group were adequate (mean 5.96 × 106 CD34+ cells/kg), and mobilization failure occurred in only 6% of patients, comparable to the 2–7% failure rates reported in the MASTER/GRIFFIN analysis (10) and the Italian multicenter study (2).

We observed a significantly deeper pre-mobilization response in our daratumumab group (≥VGPR 72% vs. 45.9%, p<0.001), which aligns with the response improvements reported in the CASSIOPEIA trial (3) and the GRIFFIN study (5).

The Italian multicenter D-VTd study explicitly noted that the higher plerixafor use represented an additional cost burden compared with historical VTd-only experience (2), and a real-world cohort study found that daratumumab exposure was associated with a higher proportion of failed planned collections and more rescue plerixafor, adding to institutional costs (11, 16).

Although we did not analyze the outcomes of ASCT regarding engraftment, the literature demonstrates that neutrophil recovery is not compromised after daratumumab-containing induction, with median times of 12 days across the MASTER, GRIFFIN, and CASSIOPEIA trials (3, 12, 13). The DILEMMA study did note increased platelet transfusion requirements at first ASCT, suggesting a subtle effect on megakaryocytic recovery that warrants further investigation (17).

A particularly relevant observation from the recent literature is the high proportion of unused stem cell grafts. The real-world analysis by Röhnert et al. reported that after a median follow-up of 4.6 years, 45% of collected grafts remained unused, with 51% unused in the Dara-VTd group and 38% in the VCd group (11). This raises clinical and economic questions about whether the traditional collection target of 4–6 × 106 CD34+ cells/kg for potential tandem or salvage ASCT remains justified in the era of highly effective quadruplet induction, and CAR-T cells and bispecific antibodies in relapsed MM setting (18). Our own data, with a median total yield of approximately 6 × 106 CD34+ cells/kg in the daratumumab group, suggests that many patients may be collecting more cells than ultimately needed, and a lower target could reduce plerixafor use, apheresis days, and storage costs without compromising current outcomes.

Several limitations of our study merit consideration. The retrospective, single-center design introduces potential selection bias, and the non-randomized comparison is subject to confounding by indication. Compared with the non-daratumumab cohort, the daratumumab cohort had a higher proportion of high-risk cytogenetics (31.7% vs. 12.0%), more frequent lenalidomide exposure (79.3% vs. 67.7%), and a higher rate of ≥VGPR before mobilization (72.0% vs. 45.9%). Although the logistic regression model mutually adjusted for daratumumab and lenalidomide exposure, it did not account for the other cohort differences. Residual confounding therefore limits attribution of the observed mobilization differences to daratumumab alone; more comprehensive adjustment is needed before an independent effect can be inferred. The predominantly steady-state mobilization regimen differs from the chemo mobilization used in many published trials, limiting direct cross-study comparisons of absolute CD34+ cell counts (10, 19). Additionally, we did not report engraftment outcomes or long-term graft utilization, which would further contextualize the clinical relevance of our findings.

In conclusion, daratumumab-based induction was associated with lower peripheral blood CD34+ cell counts and higher plerixafor requirements in our real-world cohort. These associations should not be interpreted as an independent effect of daratumumab, given the cohort imbalances and limited adjustment for potential confounding. However, with on-demand plerixafor use, successful collection and ASCT are achievable in nearly all patients, consistent with the broader literature (11, 20, 21) The association between lenalidomide exposure and plerixafor use after adjustment for daratumumab exposure underscores the importance of considering concomitant IMiD exposure when planning mobilization. Our findings support the need for tailored mobilization strategies that balance collection efficiency with cost-effectiveness, and raise the question of whether current collection targets should be re-evaluated in light of the declining use of tandem and salvage ASCT in the modern treatment landscape (20, 22). Future prospective studies should address optimal collection targets, the cost-effectiveness of upfront versus rescue plerixafor strategies, and long-term graft utilization to guide evidence-based practice.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by University Medical Center Ethics Comitee, (reference number KSEV-4-091225). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because Patient consent was waived due to the retrospective nature of the study, appliance to local laws and the use of pseudo anonymized data.

Author contributions

BS: Conceptualization, Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing. LC: Conceptualization, Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing. MS: Conceptualization, Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

B.S has received consulting fees from Amgen, Johnson & Johnson, Astra Zeneca and AbbVie; honoraria for lectures, presentations, or educational events from Amgen, Johnson & Johnson, Takeda, Ely Lilly and AbbVie. L.C. nothing to disclose. M.S. has received consulting fees from BeOne, Johnson & Johnson, and AbbVie; honoraria for lectures, presentations, or educational events from BeOne, Amgen, Johnson & Johnson, Roche, and AbbVie; and support for attending meetings and/or travel from AbbVie, holds/had held stock or stock options in BeOne, Sandoz, and AbbVie. M.S. reports holding an unpaid leadership role as President of the national hematology association.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. The authors would like to acknowledge the use of generative artificial intelligence (AI) technologies in the preparation of this manuscript. Specifically, Claude (Anthropic) was used to assist in the writing and structuring of the text. Additionally, the Posit Assistant within RStudio was utilized to support the statistical analysis and coding process. All final content, data interpretations, and conclusions remain the sole responsibility of the authors.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    DimopoulosMATerposEBoccadoroMMoreauPMateosM-VZweegmanSet al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. (2025) 22:680–700. doi: 10.1038/s41571-025-01041-x

  • 2

    FazioFPassucciMMicozziJDi LandroFFianchiLZaTet al. Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group. Bone Marrow Transplant. (2024) 59:896–8. doi: 10.1038/s41409-024-02260-z

  • 3

    MoreauPAttalMHulinCArnulfBBelhadjKBenboubkerLet al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. (2019) 394:29–38. doi: 10.1016/S0140-6736(19)31240-1

  • 4

    SonneveldPDimopoulosMABoccadoroMQuachHHoPJBeksacMet al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. (2024) 390:301–13. doi: 10.1056/NEJMoa2312054

  • 5

    VoorheesPMSborovDWLaubachJKaufmanJLReevesBRodriguezCet al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. (2023) 10:e825–37. doi: 10.1016/S2352-3026(23)00217-X

  • 6

    ShahEEYoungRPWongSWDamonLEWolfJLShahNDet al. Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma. Biol Blood Marrow Transplant. (2020) 26:876–83. doi: 10.1016/j.bbmt.2019.11.024

  • 7

    MinaRPetrucciMTBonelloFBongarzoniVSaccardiRBertugliaGet al. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and “on-demand” plerixafor in multiple myeloma patients treated with novel agents. Haematologica. (2024) 109:1525–34. doi: 10.3324/haematol.2023.284023

  • 8

    WorelNBilginYMWuchterP. Mobilization and collection of HSCThe EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies (2024). Cham (CH): Springer. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK608247/ (Accessed September 16, 2026).

  • 9

    KarpovaDRitcheyJKHoltMSAbou-EzziGMonlishDBatoonLet al. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. Blood. (2017) 129:2939–49. doi: 10.1182/blood-2016-10-746909

  • 10

    ChhabraSCallanderNWattsNLCostaLJThapaBKaufmanJLet al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. (2023) 29:174.e1–174.e10. doi: 10.1016/j.jtct.2022.11.029

  • 11

    RöhnertMASeifertATrautmann‐GrillKRölligCZimmerKEgger‐HeidrichKet al. Steady‐state mobilization with on‐demand plerixafor after CD38 antibody‐based induction in multiple myeloma patients. Transfusion. (2026) 66:751–62. doi: 10.1111/trf.70165

  • 12

    VoorheesPMKaufmanJLLaubachJSborovDWReevesBRodriguezCet al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. (2020) 136:936–45. doi: 10.1182/blood.2020005288

  • 13

    CostaLJChhabraSMedvedovaEDholariaBRSchmidtTMGodbyKNet al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. (2022) 40:2901–12. doi: 10.1200/JCO.21.01935

  • 14

    MinaRGaribaldiBBertugliaGCassonASarinaBGayFet al. Impact of daratumumab on hematopoietic stem cell mobilization with G-CSF and on-demand plerixafor in newly-diagnosed multiple myeloma patients. Blood. (2023) 142:6633. doi: 10.1182/blood-2023-180082

  • 15

    VargaCRobinsonMGuptaVHofmeisterCCNookaAKKaufmanJLet al. Stem cell mobilization yields with daratumumab (Dara) and lenalidomide (Len)-containing quadruplet induction therapy in patients with newly diagnosed multiple myeloma (NDMM): a real-world experience at 2 institutes. Clin Lymphoma Myeloma Leukemia. (2025) 25:e563–9. doi: 10.1016/j.clml.2025.04.003

  • 16

    PassosRMAMarcolinoMAZPassosJACalsavaraVFde Lourdes Martins PerobelliLCampolinaAGet al. Cost‐effectiveness of preemptive plerixafor versus rescue plerixafor for mobilization and collection of hematopoietic stem cells in patients with multiple myeloma and lymphoma. J Clin Apher. (2025) 40:e70026. doi: 10.1002/jca.70026

  • 17

    ValentiniCGPellegrinoCChiusoloPRossiELadianaRZaTet al. The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study. Haematologica. (2026) 111:1443–8. doi: 10.3324/haematol.2025.288411

  • 18

    WangY-NZhangC-WGaoY-XGeX-L. The progress of autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma (review). Technol Cancer Res Treat. (2025) 24:15330338251321349. doi: 10.1177/15330338251321349

  • 19

    BilginYM. Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantations: an update. J Blood Med. (2021) 12:403–12. doi: 10.2147/JBM.S307520

  • 20

    AviganZMArinsburgSPanDMarkTFauselCBubaloJet al. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant. (2024) 59:1440–8. doi: 10.1038/s41409-024-02385-1

  • 21

    JantunenEPartanenATurunenAVarmavuoVSilvennoinenR. Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation. Transfus Med Hemother. (2023) 50:438–47. doi: 10.1159/000531940

  • 22

    DhakalBZhangM-JBurnsLJTangXMeyerCMauL-Wet al. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. (2023) 108:2249–54. doi: 10.3324/haematol.2022.282269

Summary

Keywords

autologous stem cell transplant (ASCT), daratumumab, mobilization, mobilization failure, multiple myeloma, plerixafor, stem cell collection

Citation

Skopec B, Cemazar L and Skerget M (2026) Stem cell mobilization with G-CSF and on-demand plerixafor in newly diagnosed multiple myeloma patients treated with daratumumab: a single-center experience. Front. Oncol. 16:2002517. doi: 10.3389/fonc.2026.2002517

Received

18 September 2026

Revised

19 October 2026

Accepted

26 October 2026

Published

04 November 2026

Volume

16 - 2026

Edited by

Jelena Bila, University of Belgrade, Serbia

Reviewed by

Sorina Nicoleta Badelita, Fundeni Clinical Institute, Romania

Durga Chougule, Indian Council of Medical Research, India

Updates

Copyright

*Correspondence: Barbara Skopec,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics